BioPhausia's sale of major portion of dextran operations to Pharmalink is completed

BioPhausia's sale of major portion of dextran operations to Pharmalink is completed Implementation by BioPhausia and Pharmalink of a transaction in which Pharmalink acquires the major part of BioPhausia's dextran operations is an important step in restructuring BioPhausia as a purely research and development company. In this transaction, which was announced previously, Pharmalink is acquiring BioPhausia's entire international operations for the existing dextran-based intravenous pharmaceutical products. "We are very pleased about this deal," says BioPhausia's Vice-president, Richard Hainsworth. "The final stage in our restructuring process will be the sale of the Hyskon® gynecology product, which is primarily marketed in the US. We aim to do this in the near future." "Our total sales volume will increase to more than SEK 100 M as a result of this transaction, Mikael Bender, Pharmalink's President says. "In addition, we will be extending our international network to facilitate more rapid expansion of our overall operations. Our dextran strategy also includes starting up a new development project in 1998." Uppsala, November 20, 1997 Based on its contact network and know-how, primarily in connective-tissue biology, BioPhausia is developing products for licensing to well-established pharmaceutical companies with strong marketing organizations. The project portfolio includes RescueFlow®, a resuscitation solution (registration phase), Krillase® for the debridement of chronic wounds (clinical phase III), and preclinical projects in the tumor and trauma treatment areas. Please contact the President, Stellan Lind, or the Vice-president, Richard Hainsworth for further information. Tel. +46-18-34 99 00 Pharmalink Basläkemedel AB specializes in development and sales of pharmaceutical to hospitals. The company was founded in 1991 and currently has sales of approximately SEK 40 M in its two principal areas, anesthesia and dialysis. Please contact the President, Mikael Bender, for further information. Tel. +46-8-757 62 90